Tengion to Present at 27th Annual JP Morgan Healthcare Conference
Breakthrough in Kidney Regeneration Program: Preclinical Progress to be Highlighted
EAST NORRITON, Pa., Jan. 6 /PRNewswire/ -- Tengion Inc., a clinical-stage organ regeneration company with products in urologic, vascular, and renal regeneration, today announced that Steven Nichtberger, M.D., president and chief executive officer, is scheduled to present at the 27th Annual JP Morgan Healthcare Conference on Monday, January 12, 2009 at 2:30 p.m. PST. The conference will be held January 12 - 15 at The Westin St. Francis Hotel in San Francisco.
For the first time, Dr. Nichtberger will discuss Tengion's completion of its Phase 2 clinical trial in patients with neurogenic bladder due to spina bifida and the company's plans for a Phase 3 trial of its Tengion Neo-Bladder Augment(R) in patients with neurogenic bladder, planned for initiation in the first half of 2009. Dr. Nichtberger will also present breakthrough preclinical data from Tengion's renal program.
"Regenerative medicine is on the verge of unimagined breakthroughs. Similar to the emergence of novel chemical, protein, and antibody therapeutics in the past few decades, the impact of regenerative medicine on human health is emerging with great promise in the new millennium," said Dr. Nichtberger. "Tengion is at the forefront of this space with a practical and proven organ regeneration technology platform with nearly a decade of human clinical experience. Recent preclinical advances in our renal program, which is focused on eliminating the need for dialysis in patients with emerging kidney failure, reinforce the promise and value of our technology platform. The past year has been filled with important milestones that position us well for 2009."
"Kidney regeneration from patients' own cells would become the standard of care for chronic renal failure therapy. Tengion's work on the neo-kidney is an important early step towards this goal," said Brian Pereira, MD, former President of the National Kidney Foundation, editor of the leading textbook, "Chronic Kidney Disease, Dialysis, & Transplantation," and Board member of Tengion, Inc.
Tengion is a clinical-stage organ regeneration company with products in urologic, vascular and renal regeneration based on its proprietary Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion is a fully-integrated organization, with scalable U.S. and European manufacturing and distribution capabilities, experienced research, development, clinical and commercial teams, and significant intellectual property. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information, please visit www.tengion.com.
You May Also Like